The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)

被引：0
|
作者：
Sumii, Toshihiko [1 ]
Fujimori, Nao [1 ]
Funakoshi, Akihiro [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Dept Gastroenterol, Fukuoka, Japan
来源：
PANCREAS | 2008年 / 37卷 / 01期
关键词：
D O I：
10.1097/01.mpa.0000325612.89290.b5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [41] Phase II study of carboplatin and irinotecan (CPT-11) in patients with limited disease small cell lung cancer (SCLC)
    Laack, E.
    Boeters, I.
    Kruell, A.
    Engel-Riedel, W.
    Mueller, T.
    Meibner, R.
    Duerk, H.
    Burkholder, I.
    Hossfeld, D. K.
    Bokemeyer, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 328 - 328
  • [42] Irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study.
    Cohen, Y
    Shulman, K
    Idelevich, E
    Ben-Shachar, M
    Honnigman, J
    Haiat, H
    Zidan, J
    Hubert, A
    Kuten, A
    Beny, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 304S - 304S
  • [43] Phase II study of irinotecan (CPT 11) in patients whit not pretreated advanced colorectal cancer.
    Salgado, M
    Menéndez, D
    Sabin, P
    Diz, P
    Constenia-Figueiras, M
    Casai, J
    Calvo, L
    Castellanos, J
    Balcells, M
    Firvida, JL
    Irigoyen, A
    Quintero, G
    Garcia-Palomo, A
    García-Arroyo, FR
    Huidobro, G
    Valladares, M
    Garcia-Mata, J
    Vázquez, S
    De las Peñas, R
    Lorenzo, I
    Xaries, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [44] A combination phase I study of amrubicin and irinotecan (CPT-11) in patients with lung cancer.
    Kurata, T
    Kaneda, H
    Tamura, K
    Satoh, T
    Nogami, T
    Uejima, H
    Nakagawa, K
    Fukuoka, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 703S - 703S
  • [45] Phase II trial of irinotecan (CPT-11) and radiation followed by irinotecan and BCNU in glioblastoma patients (pts).
    Ballman, K. V.
    Jaeckle, K. A.
    Schomberg, P.
    Giannini, C.
    Galanis, E.
    Brown, P.
    Arusell, R.
    Reid, J.
    Hammack, J.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 73S - 73S
  • [46] The efficacy of irinotecan (CPT-11) and mitomycin C (MMC) as second line chemotherapy: Preliminary report of a phase II trial in gastric cancer
    Tadaoka, N
    Inomata, Y
    Nakamura, Y
    Sakuyama, T
    Takahashi, N
    Otani, M
    Takayama, S
    Aoki, T
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 1571 - 1573
  • [47] Irinotecan (CPT-11) plus raltitrexed as second line chemotherapy (CT) in metastatic colorectal cancer: A phase II study. Preliminary results.
    Caroti, C
    Aschele, C
    Mammoliti, S
    D'Amico, M
    Torrisi, R
    Gallo, L
    ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
  • [48] Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy
    García-Girón C.
    Palomo A.G.
    López C.A.
    Carbonero A.L.
    Ureña M.M.
    Cebrián E.A.
    Galíndez R.B.
    Yustos M.A.
    Gallego J.A.
    Clinical and Translational Oncology, 2005, 7 (6) : 244 - 249
  • [49] Irinotecan (CPT-11) as first line treatment of patients with not pretreated advanced colorectal cancer
    Firyida, JL
    Menendez, MD
    Mel, JR
    Diz, P
    Constenla-Figueiras, M
    Casal, J
    Valladares, M
    Castellanos, J
    Balcells, M
    ANNALS OF ONCOLOGY, 1998, 9 : 38 - 39
  • [50] Phase II study of S-1 in combination with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer (KSCOG-BC01)
    Toh, U.
    Fukushima, T.
    Fukunaga, M.
    Iwakuma, N.
    Takenaka, M.
    Otsuka, H.
    Shirouzu, K.
    Ogo, E.
    EJC SUPPLEMENTS, 2010, 8 (03): : 204 - 204
12345